Suchergebnisse - "O'Connor, Owen A"

PubPharm (11)

1

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

enthalten in: Blood advances | 2022

von Savage, K. | Horwitz, S. | Advani, R. | +21

2

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Horwitz, S. | O'Connor, O. | Pro, B. | +129

CommentIn: Lancet. 2019 Jan 19;393(10168):201-202. - PMID 30663580

3

Brentuximab vedotin plus bendamustine : a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

enthalten in: Blood | 2018

von LaCasce, A. | Bociek, R. | Sawas, A. | +14

CommentIn: Blood. 2018 Jul 5;132(1):1-3. - PMID 29976776

4

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma : an international, multicentre, single-arm, phase 1-2 trial

enthalten in: The Lancet. Oncology | 2018

von O'Connor, O. | Lue, J. | Sawas, A. | +19

CommentIn: Lancet Oncol. 2018 Feb;19(2):162-163. - PMID 29276023

5

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

enthalten in: Leukemia & lymphoma | 2017

von Bartlett, N. | Smith, M. | Siddiqi, T. | +13

CommentIn: Leuk Lymphoma. 2017 Jul;58(7):1524-1525. - PMID 28278730

6

Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

enthalten in: Hematology/oncology clinics of North America | 2017

von Marchi, E. | Raufi, A. | O'Connor, O.

7

Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment

enthalten in: British journal of clinical pharmacology | 2016

von Zhao, B. | Chen, R. | O'Connor, O. | +7

8

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

enthalten in: Blood | 2014

von Horwitz, S. | Advani, R. | Bartlett, N. | +6

CommentIn: Blood. 2014 May 15;123(20):3059-60. - PMID 24832935

9

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies

enthalten in: Journal of clinical pharmacology | 2013

von Han, T. | Gopal, A. | Ramchandren, R. | +8

10

Brentuximab vedotin

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2013

von Deng, C. | Pan, B. | O'Connor, O.